Integer Holdings Corporation Faces Class Action Lawsuit for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy ITGR?
Source: Globenewswire
- Lawsuit Notification: Levi & Korsinsky LLP informs investors that Integer Holdings Corporation is facing a class action lawsuit for alleged securities fraud covering the period from July 25, 2024, to October 22, 2025, which may result in significant investor losses.
- False Statements Allegations: The lawsuit alleges that Integer overstated its competitive position in the electrophysiology manufacturing market and concealed a sustained decline in sales of its electrophysiology devices, impacting the company's long-term growth prospects in the cardiovascular segment.
- Investor Rights Protection: Affected investors have until February 9, 2026, to request to be appointed as lead plaintiff, allowing them to seek compensation without incurring any out-of-pocket costs or fees for participation in the lawsuit.
- Legal Team Strength: Levi & Korsinsky has over 20 years of experience in securities litigation, having secured hundreds of millions of dollars for aggrieved shareholders, demonstrating its expertise and successful track record in complex securities cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 85.230
Low
75.00
Averages
93.38
High
140.00
Current: 85.230
Low
75.00
Averages
93.38
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Against Integer Holdings
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings (NYSE: ITGR) common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology (EP) manufacturing market and failed to disclose a sustained decline in sales of its EP devices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Integer Holdings Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Rosen Law Firm has alerted investors about a class action lawsuit on behalf of purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock from July 25, 2024, to October 22, 2025, alleging significant exaggeration of its competitive position in the electrophysiology manufacturing market.
- False Statement Allegations: The lawsuit claims that Integer's assertions of strong visibility into customer demand contradicted the reality of deteriorating sales for two of its electrophysiology devices, resulting in investor losses when the truth emerged.
- Market Impact: As the true details became public, investors realized that Integer's positive statements lacked a reasonable basis, potentially leading to significant stock price impacts and revealing serious misguidance regarding the company's growth prospects in the cardiovascular device sector.
- Legal Proceedings Update: Investors wishing to serve as lead plaintiffs in the class action must file their motions with the court by February 9, 2026, indicating their representative role in the litigation, and they do not need to participate in the case to be eligible for recovery.
See More
Integer Holdings Corporation Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Integer Holdings Corporation and certain executives for securities fraud, following a significant stock drop due to potential violations of federal securities laws.
- Stock Price Plunge: On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, below analyst expectations, causing its stock price to plummet from $109.11 to $73.89, a drop of over 32%.
- False Performance Claims: The lawsuit alleges that Integer overstated demand for its electrophysiology devices, while actual sales and demand sharply declined, contradicting the company's public assurances.
- Legal Options: Investors are encouraged to apply to lead the case by February 9, 2026, with BFA offering representation on a contingency fee basis, ensuring no upfront costs for shareholders.
See More
Integer Holdings Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by February 9, 2026, for the securities class action against Integer Holdings, involving trades from July 25, 2024, to October 22, 2025, highlighting the urgency of legal proceedings and potential investor rights.
- Sales Guidance Cut: On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, significantly below analyst expectations, with projected net sales growth of -2% to 2% for 2026, indicating slower market adoption of its products and potential impacts on future performance.
- Stock Price Plunge: Following the sales guidance cut, Integer's stock price plummeted by $35.22, or over 32%, from a closing price of $109.11 on October 22, 2025, to $73.89 on October 23, reflecting market pessimism regarding the company's outlook.
- Legal Liability Allegations: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, undermining investor confidence.
See More
Reminder for Integer Holdings Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology market and failed to disclose a sustained decline in sales of two of its devices, resulting in investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resources, urging investors to choose counsel with a proven track record.
- Investor Rights Protection: Until the class is certified, investors can select their own counsel or choose to remain absent, ensuring that their ability to share in any potential recovery is not contingent on serving as lead plaintiff, thus protecting their rights.
See More
Class Action Lawsuit Filed Against Integer Holdings Corporation
- Lawsuit Background: Bragar Eagel & Squire, P.C. has filed a class action lawsuit in the Southern District of New York against Integer Holdings Corporation on behalf of investors who purchased common stock between July 25, 2024, and October 22, 2025, alleging that the company materially overstated its competitive position in the EP manufacturing market.
- Allegation Details: The complaint claims that despite the company's assertions of strong visibility into customer demand, it was experiencing a sustained decline in sales of two EP devices, misrepresenting their role as long-term growth drivers for the C&V segment, thus misleading investors about the company's business prospects.
- Investor Rights: Affected investors must apply by February 9, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and potential claims.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive experience in protecting investor rights across federal and state courts.
See More
Notice of Class Action Against Integer Holdings
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings (NYSE: ITGR) common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology (EP) manufacturing market and failed to disclose a sustained decline in sales of its EP devices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Integer Holdings Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Rosen Law Firm has alerted investors about a class action lawsuit on behalf of purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock from July 25, 2024, to October 22, 2025, alleging significant exaggeration of its competitive position in the electrophysiology manufacturing market.
- False Statement Allegations: The lawsuit claims that Integer's assertions of strong visibility into customer demand contradicted the reality of deteriorating sales for two of its electrophysiology devices, resulting in investor losses when the truth emerged.
- Market Impact: As the true details became public, investors realized that Integer's positive statements lacked a reasonable basis, potentially leading to significant stock price impacts and revealing serious misguidance regarding the company's growth prospects in the cardiovascular device sector.
- Legal Proceedings Update: Investors wishing to serve as lead plaintiffs in the class action must file their motions with the court by February 9, 2026, indicating their representative role in the litigation, and they do not need to participate in the case to be eligible for recovery.
See More
Integer Holdings Corporation Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Integer Holdings Corporation and certain executives for securities fraud, following a significant stock drop due to potential violations of federal securities laws.
- Stock Price Plunge: On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, below analyst expectations, causing its stock price to plummet from $109.11 to $73.89, a drop of over 32%.
- False Performance Claims: The lawsuit alleges that Integer overstated demand for its electrophysiology devices, while actual sales and demand sharply declined, contradicting the company's public assurances.
- Legal Options: Investors are encouraged to apply to lead the case by February 9, 2026, with BFA offering representation on a contingency fee basis, ensuring no upfront costs for shareholders.
See More
Integer Holdings Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by February 9, 2026, for the securities class action against Integer Holdings, involving trades from July 25, 2024, to October 22, 2025, highlighting the urgency of legal proceedings and potential investor rights.
- Sales Guidance Cut: On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, significantly below analyst expectations, with projected net sales growth of -2% to 2% for 2026, indicating slower market adoption of its products and potential impacts on future performance.
- Stock Price Plunge: Following the sales guidance cut, Integer's stock price plummeted by $35.22, or over 32%, from a closing price of $109.11 on October 22, 2025, to $73.89 on October 23, reflecting market pessimism regarding the company's outlook.
- Legal Liability Allegations: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, undermining investor confidence.
See More
Reminder for Integer Holdings Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology market and failed to disclose a sustained decline in sales of two of its devices, resulting in investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resources, urging investors to choose counsel with a proven track record.
- Investor Rights Protection: Until the class is certified, investors can select their own counsel or choose to remain absent, ensuring that their ability to share in any potential recovery is not contingent on serving as lead plaintiff, thus protecting their rights.
See More
Class Action Lawsuit Filed Against Integer Holdings Corporation
- Lawsuit Background: Bragar Eagel & Squire, P.C. has filed a class action lawsuit in the Southern District of New York against Integer Holdings Corporation on behalf of investors who purchased common stock between July 25, 2024, and October 22, 2025, alleging that the company materially overstated its competitive position in the EP manufacturing market.
- Allegation Details: The complaint claims that despite the company's assertions of strong visibility into customer demand, it was experiencing a sustained decline in sales of two EP devices, misrepresenting their role as long-term growth drivers for the C&V segment, thus misleading investors about the company's business prospects.
- Investor Rights: Affected investors must apply by February 9, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and potential claims.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive experience in protecting investor rights across federal and state courts.
See More
